ANT01
Adjunctive treatment of Partially Responsive Depression (PRD) in Major Depressive Disorder
Key Facts
About ANeuroTech
ANeuroTech is a private, late-stage biotech developing ANT01, a novel adjunctive treatment for patients with Major Depressive Disorder (MDD) who respond only partially to first-line antidepressants. The drug, now in Phase III, has a unique dual mechanism of action targeting serotonin 2A and dopamine D4 receptors to address emotional blunting and cognitive impairment. Founded by psychiatrist Dr. Erik Buntinx, the company leverages deep neuroscience expertise to target a large market opportunity, with peak sales projections for ANT01 reaching into the multi-billion dollar range based on its potential superior side-effect profile compared to current atypical antipsychotic adjuncts.
View full company profile